Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

NOT YET RECRUITING

NCT05920499

The Effect of AUDIT and Feedback on Pneumococcal Vaccination Coverage

Sponsor: Bert Vaes

View on ClinicalTrials.gov

Summary

The goal of this cluster-randomized trial is to study the effect of Audit and Feedback loops on pneumococcal vaccination coverage rate in adults at risk in general practice. The main questions it aims to answer are: * To assess the effect of "clinical AUDIT and feedback" loops on the pneumococcal vaccination coverage rate in adults at risk in general practice. * To explore whether the increase in vaccination coverage rate after implementation of Audit and Feedback loops is different in specific subgroups (risk groups, male/female, age, smoking status). Every general practice center assigned to the control or intervention group will have access to a clinical AUDIT to identify patients that may benefit from a pneumococcal vaccination. The general practice centers in the intervention group will also receive an individualized extended electronic feedback report, with multiple components like benchmarked performances and action plans, at baseline and each 2 months from baseline onwards.

Official title: The Effect of AUDIT and Feedback on Pneumococcal Vaccination Coverage in Adults At Risk in General Practice: a Cluster Randomized Trial

Key Details

Gender

All

Age Range

16 Years - 85 Years

Study Type

INTERVENTIONAL

Enrollment

Start Date

2025-01-31

Completion Date

2026-03-31

Last Updated

2024-09-24

Healthy Volunteers

Conditions

Pneumococcal Infections

Interventions

OTHER

AUDIT and Feedback

AUDIT and Feedback is a well-known quality intervention that according to the last Cochrane review leads to "small but potentially important improvements in professional practice" (Ivers N et al. Audit and feedback: effects on professional practice and healthcare outcomes. Cochrane Database Syst Rev 2012, 6:Cd000259). Standardized automated AUDITs are available in most EHR systems in Belgium. Feedback, on the other hand, is only available in specific registration networks. At study baseline the performance in INTEGO practices will be measured. Afterwards a standardized clinical AUDIT to identify patients that may benefit from pneumococcal vaccination will be implemented in the EHR of all INTEGO practices. The Feedback will only be implemented in the intervention group.

Inclusion Criteria * To be eligible for inclusion in the study, general practice (GP) centers must conform to the following conditions: 1. It is a Flemish GP center in the INTEGO network. 2. The GP center uses an electronic health record (EHR), automatically linked to the INTEGO database. 3. The physician (one per center, in name of all GPs in that center) signs a specific study consent form. * To be eligible for inclusion in the study, patients must conform to the following conditions: 1. The patient belongs to a target group for pneumococcal vaccination (based on https://www.health.belgium.be/sites/default/files/uploads/fields/fpshealth\_theme\_file/hgr\_9562\_vaccinatie\_tegen\_pneumokokken\_vweb.pdf): A. Adults aged 16 - 85 years old with a high risk for a pneumococcal infection * Adults with an immunity disorder * Adults with anatomical and / or functional asplenia, sickle-cell disease or hemoglobinopathy * Adults with cerebrospinal fluid or cochlear implant leakage B. Adults (aged 50 - 85 years old) with comorbidity * Chronic cardiac disease * Chronic pulmonary disease or smoker * Chronic liver disease or ethylabusus * Chronic kidney disease * Chronic neurological or neuromuscular disorders with aspiration risk * Diabetes mellitus C. Healthy persons aged 65 - 85 years old 2. The patient has an electronic medical record (EMR) in the participating general practice centre. This EMR contains all the patient information, for instance regarding medical history and medication and is managed by the general practitioner. Exclusion criteria * Patients excluded from feedback: patients not belonging to one of the target groups for pneumococcal vaccination. * Patients excluded from AUDIT: patients not belonging to one of the target groups for pneumococcal vaccination OR * Correctly vaccinated high-risk patients (PPV23 less than 5 years ago AND PCV13 ever received) * Correctly vaccinated adults with comorbidity (1) PCV13 ever received AND PPV23 less than 5 years ago, OR 2) PCV13 ever received AND 2x PPV23 vaccination more than 5 years ago) * Correctly vaccinated healthy persons (PPV23 ever received)

Locations (1)

Academic Center of General Practice

Leuven, Belgium